• 1-800-781-0477, 1-760-231-9471
  • Email:sales@AmericanPharmaWholesale.com
  • Site Map



Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#,UPC#or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.
Menu

Ezetimibe Generic Zetia 10mg Tab 30 by Sun Pharma exp 1/19

NDC 66582-0414-28 UPC/GTIN No.3-66582-41428-5 Mfg.Part No.386128Merck & Co.This Item Can Only Be Ordered By A Drug Mfg, Wholesaler,Pharmacy,Physician, Dentist, Podiatrist, Optometrist,Veterinarian,Naturopath,Licensed Lab, Physical Therapist & Pharmacist(scope).Merck & Co.Image 4 of Ezetimibe Generic Zetia 10mg Tab 30 by Sun Pharma exp 1/19Image 5 of Ezetimibe Generic Zetia 10mg Tab 30 by Sun Pharma exp 1/19ZetiaEzetimibe Generic Zetia 10mg Tab 30 by Sun Pharma  
NDC: 51660-0200-30   
UPC: 351660-200300

Ezetimibe Generic Zetia 10mg Tab 30 by Sun Pharma exp 1/19

$308.43$4.99

NDC No.51660-0200-30 51660-200-30 UPC/GTIN No.3-51660-20030-0 MPN 20030 Only Physician,Pharmacy or Licensed Facility can order this Rx Item No.RX677981 Ezetimbe Generic Zetia 10mg Tab 30 by Sun Pharma Item No.677981NDC No.51660020030 5166020030 UPC No.351660-200300 351660200300 Other Name Zetia Therapeutic Code 240605 Therapeutic Class Cholesterol Absorption Inhibitors Item Class Non Controlled Rx. Case Qnty: 40 Therapeutic Code 240605 Cholesterol Absorption Inhibitors Info Decreased C

Have a question?

ZETIA- ezetimibe tablet
Merck Sharp & Dohme Corp.


INDICATIONS AND USAGE
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.
1.1 Primary Hyperlipidemia
Monotherapy
ZETIA ® , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia.
Combination Therapy with HMG-CoA Reductase Inhibitors (Statins)
ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia.
Combination Therapy with Fenofibrate
ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in adult patients with mixed hyperlipidemia.
1.2 Homozygous Familial Hypercholesterolemia (HoFH)
The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
1.3 Homozygous Sitosterolemia
ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.
1.4 Limitations of Use
The effect of ZETIA on cardiovascular morbidity and mortality has not been determined.
ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.
2 DOSAGE AND ADMINISTRATION
2.1 General Dosing Information
The recommended dose of ZETIA is 10 mg once daily.
ZETIA can be administered with or without food.
2.2 Concomitant Lipid-Lowering Therapy
ZETIA may be administered with a statin (in patients with primary hyperlipidemia) or with fenofibrate (in patients with mixed hyperlipidemia) for incremental effect. For convenience, the daily dose of ZETIA may be taken at the same time as the statin or fenofibrate, according to the dosing recommendations for the respective medications.
DOSAGE FORMS AND STRENGTHS
10-mg tablets are white to off-white, capsule-shaped tablets debossed with "414″ on one side.
DESCRIPTION
ZETIA (ezetimibe) is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. The chemical name of ezetimibe is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C24 H21 F2 NO3 .
CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. In a 2-week clinical study in 18 hypercholesterolemic patients, ZETIA inhibited intestinal cholesterol absorption by 54%, compared with placebo. ZETIA had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E (in a study of 113 patients), and did not impair adrenocortical steroid hormone production (in a study of 118 patients).
The cholesterol content of the liver is derived predominantly from three sources. The liver can synthesize cholesterol, take up cholesterol from the blood from circulating lipoproteins, or take up cholesterol absorbed by the small intestine. Intestinal cholesterol is derived primarily from cholesterol secreted in the bile and from dietary cholesterol.
Ezetimibe has a mechanism of action that differs from those of other classes of cholesterol-reducing compounds (statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols.
Ezetimibe does not inhibit cholesterol synthesis in the liver, or increase bile acid excretion. Instead, ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of statins and of fenofibrate


NDC 66582-0414-28 UPC/GTIN No.3-66582-41428-5 Mfg.Part No.386128
Zetia 10mg Tab 100 by Merck
NDC 66582-0414-28 UPC/GTIN No.3-66582-41428-5 Mfg.Part No.386128

Merck & Co.

Merck & Co.

This Item Can Only Be Ordered By A Drug Mfg, Wholesaler,Pharmacy,Physician, Dentist, Podiatrist, Optometrist,Veterinarian,Naturopath,Licensed Lab, Physical Therapist & Pharmacist(scope).
EZETIMIBE ORAL TABLET 10
This Item Can Only Be Ordered By A Drug Mfg, Wholesaler,Pharmacy,Physician, Dentist, Podiatrist, Optometrist,Veterinarian,Naturopath,Licensed Lab, Physical Therapist & Pharmacist(scope).

Merck & Co.
Merck & Co.

Image 4 of Ezetimibe Generic Zetia 10mg Tab 30 by Sun Pharma exp 1/19

Image 5 of Ezetimibe Generic Zetia 10mg Tab 30 by Sun Pharma exp 1/19

Zetia
Click above for Brand!
Zetia

Ezetimibe Generic Zetia 10mg Tab 30 by Sun Pharma  
NDC: 51660-0200-30   
UPC: 351660-200300
51660-0200-30
Ezetimibe Generic Zetia 10mg Tab 30 by Sun Pharma NDC: 51660-0200-30 UPC: 351660-200300